Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
SKRR to Commence Uranium Drill Program to Test Conductors at Clearwater West (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Myriad Genetics Inc MYGN

Healthcare Biotechnology
Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has... see more

Recent & Breaking News (NDAQ:MYGN)

Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance

GlobeNewswire November 6, 2023

Myriad Genetics Appoints Sam Raha as Chief Operating Officer

GlobeNewswire November 1, 2023

Myriad Genetics to Release Third Quarter Financial Results on November 6, 2023

GlobeNewswire October 31, 2023

QIAGEN and Myriad Genetics partner to advance companion diagnostics development for cancer

GlobeNewswire October 26, 2023

BREAST CANCER AWARENESS MONTH: NEW CANCER RISK SURVEY REVEALS RISK FACTORS ARE WIDELY MISUNDERSTOOD

PR Newswire September 28, 2023

New Myriad Genetics Survey Shows Breast Cancer Risk Factors Are Misunderstood

GlobeNewswire September 28, 2023

Myriad Genetics and Illumina Achieve Milestones in Strategic Partnership to Support Biopharma Clinical Trials

GlobeNewswire September 19, 2023

Myriad Genetics Issues 2022 Environmental, Social and Governance Report

GlobeNewswire September 19, 2023

Myriad Genetics and Leading Cancer Center Collaborate to Study the Use of Minimal Residual Disease Testing in Breast Cancer

GlobeNewswire September 18, 2023

Myriad Genetics Named to 2023 Best Workplaces in Health Care List by Fortune and Great Place To Work

GlobeNewswire September 6, 2023

New Myriad Genetics Survey Reveals Widespread Confusion and Misconceptions About Ovarian Cancer Screening Among a Majority of Women

GlobeNewswire September 6, 2023

Myriad Genetics to Participate in Morgan Stanley Global Healthcare Conference

GlobeNewswire September 5, 2023

Myriad Genetics and Onsite Women's Health Partner to Help More Women Understand Breast Cancer Risk

GlobeNewswire August 22, 2023

Myriad Genetics to Host Investor Day on September 19, 2023

GlobeNewswire August 17, 2023

Myriad Genetics Advances Prostate Cancer Care with Addition of Absolute Risk Reduction to Prolaris®

GlobeNewswire August 15, 2023

Myriad Genetics and Intermountain Health Participate in ComboMATCH, a National Clinical Trial to Advance Cancer Treatment

GlobeNewswire August 8, 2023

Myriad Genetics Announces Enhancements to the GeneSight® Test to Personalize Mental Health Medication Treatment Decisions Based on Smoking Status

GlobeNewswire August 7, 2023

Myriad Genetics Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Revenue and Adjusted EPS Guidance; Generates the Fourth Consecutive Quarter of Double-Digit Year-Over-Year Testing Volume Growth

GlobeNewswire August 3, 2023

Myriad Genetics to Release Second Quarter Financial Results on Aug. 3, 2023

GlobeNewswire July 27, 2023

Myriad Genetics Announces Inclusion of Breast Density to MyRisk® with RiskScore® Breast Cancer Risk Assessment

GlobeNewswire July 24, 2023